NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks. In this phase 2 portion of a phase 1–2 trial ...

Their test, described as the four-kallikrein panel, assays the blood levels of the three subtypes of PSA (complex, intact and nicked) and hK2, a molecule involved in PSA activation. Andrew Vickers ...

The lower 25mg dose corresponded to a 55% reduction in plasma kallikrein, while the 50mg dose reduced levels by 86%. The dose ...

RZ402 is a plasma kallikrein inhibitor for retinal-vascular complications of diabetes mellitus such as diabetic macular edema, a leading and growing cause of blindness in working-age adults.

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of the disease and edited a gene in the livers of nonhuman primates ...

Sian Harding was born with a rare debilitating condition called hereditary angioedema (HAE) which causes swelling from head ...

BioCryst Pharmaceuticals ( (BCRX) ) has released its Q3 earnings. Here is a breakdown of the information BioCryst Pharmaceuticals presented to ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Hereditary Angioedema Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight ...

Opens in a new tab or window A single dose of the CRISPR-based gene-editing therapy NTLA-2002 reduced angioedema attacks and led to sustained reduction in total plasma kallikrein protein levels ...

Fintel reports that on November 5, 2024, Wedbush initiated coverage of Rezolute (NasdaqCM:RZLT) with a Outperform ...

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today reported financial results for the third quarter ended September 30, 2024, and ...